Altimmune (ALT) news

Altimmune 2Q loss/share 12c, est. loss/share 14c

Altimmune, Inc. (Nasdaq: ALT) reported a net loss of $0.32 per share for the second quarter of 2023, matching the midpoint of its guidance . This represents an improvement compared to the $0.42 net loss per share in the same period in 2022. The company’s net loss for the quarter totaled $16.1…

Altimmune 2Q R&D expenses $18.7M, est. $18.6M

Altimmune, Inc. (Nasdaq: ALT) reported research and development (R&D) expenses of $18.7 million for the second quarter of 2026, slightly exceeding the estimated $18.6 million . The company continues to advance its lead product candidate, pemvidutide, across multiple therapeutic areas, including…

Altimmune - 52-week data readout from Performa Phase 3 trial anticipated in 2029

Altimmune, Inc. (Nasdaq: ALT) has outlined plans for its PERFORMA Phase 3 trial of pemvidutide in the treatment of metabolic dysfunction-associated steatohepatitis (MASH), with a 52-week data readout anticipated in 2029. The trial is expected to begin in the second half of 2026, following the…

Altimmune shares up 10% as co's drug meets main goal of mid-stage study for alcohol use disorder

Altimmune, Inc. (Nasdaq: ALT) reported a 10% increase in its stock price following the announcement that its mid-stage clinical trial, RECLAIM, met its primary endpoint in evaluating pemvidutide for the treatment of Alcohol Use Disorder (AUD). The trial, which enrolled approximately 100 subjects…

Altimmune shares up 17% premarket as co's drug meets main goal of mid-stage study for alcohol use disorder